- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Suven Pharmaceuticals Limited held a meeting of equity shareholders to approve the Scheme of Amalgamation with Cohance Lifesciences Limited, as directed by the NCLT. The scheme received overwhelming support, with over 99.99% of votes in favor, showcasing strong shareholder confidence in this strategic move. The amalgamation aims to enhance operational synergies, positioning Suven for improved growth and profitability. This positive outcome reflects a favorable investor sentiment, potentially increasing market interest in the company's future trajectory post-amalgamation. Overall, the event heightens the outlook for Suven amidst consolidation in the pharmaceutical sector.